Zobrazeno 1 - 10
of 1 742
pro vyhledávání: '"ALK Inhibitor"'
Autor:
Johana Benedetti Pedroza, Irene Carrasco García, Gala Martínez Bernal, Isabel Miras Rodriguez
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 763-772 (2024)
Introduction: Inflammatory myofibroblastic tumor (IMT) is a rare entity, classified within soft tissue sarcomas. It is an intermediate malignancy tumor, which seldom presents as metastatic disease. The treatment of choice is surgery, except in cases
Externí odkaz:
https://doaj.org/article/b4126599924348d9b506d42e44f7dab1
Autor:
Stav Cullum, Hlu Vang, Michael Glover, Howra Alammarah, Heather Morton, Nancy Pham, Mobeen Rahman, Saad A. Khan
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
In the era of targeted therapies, the clinical importance and utility of next-generation sequencing (NGS) has expanded significantly. Owing to the relative ease and financial feasibility of NGS, the use of personalized treatment strategies has the po
Externí odkaz:
https://doaj.org/article/31b55fcf341144be8556b6592934ac3f
Publikováno v:
European Journal of Case Reports in Internal Medicine (2024)
Introduction: EML4-ALK is an oncogenic driver, seen in around five per cent of advanced non-small-cell lung cancer (NSCLC) patients, which can be targeted with anaplastic lymphoma kinase tyrosine kinase inhibitors with great response rates. Disease f
Externí odkaz:
https://doaj.org/article/5cc2f2a73d214a4485c81818558868f7
Autor:
Bei Zheng, Hong Jiang, Wenjuan Yang, Ying Li, Bingqing Liang, Jun Zhu, Nanmei Chen, Miao Chen, Meiling Zhang
Publikováno v:
Cancer Medicine, Vol 12, Iss 15, Pp 15983-15997 (2023)
Abstract Objective To date, no direct comparisons have compared the effectiveness of all ALK inhibitors (ALKis) against ALK‐positive non‐small cell lung cancer (NSCLC). The aim of the present study was to investigate the efficacy and safety of AL
Externí odkaz:
https://doaj.org/article/ce9b364342e7468b98811056f2c41610
Autor:
Makito Tanaka, Hiroki Miura, Soichiro Ishimaru, Gen Furukawa, Yoshiki Kawamura, Kei Kozawa, Seiji Yamada, Fumitaka Ito, Kazuko Kudo, Tetsushi Yoshikawa
Publikováno v:
Pediatric Reports, Vol 15, Iss 2, Pp 333-340 (2023)
Central nervous system (CNS) involvement in anaplastic large cell lymphoma (ALCL) at diagnosis is rare and leads to poor prognosis with the use of the standard ALCL99 protocol alone. CNS-directed intensive chemotherapy, such as an increased dose of i
Externí odkaz:
https://doaj.org/article/9a92fffc0fdf48aab1565e704103729f
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Fusions and mutations of anaplastic lymphoma kinase (ALK), a tyrosine kinase receptor, have been identified in several neoplastic diseases. Rearranged ALK is a driver of tumorigenesis, which activates various signaling pathway associated with prolife
Externí odkaz:
https://doaj.org/article/d26ac8665cf74b16a665d67263a96168
Publikováno v:
Cancer Medicine, Vol 12, Iss 6, Pp 7182-7188 (2023)
Abstract Approximately one‐third children with anaplastic large cell lymphoma (ALCL) relapse after completion of chemotherapy, particularly for those high‐risk patients. The introduction of novel therapeutic modalities is much needed for these su
Externí odkaz:
https://doaj.org/article/e12910ccbd064567b6317e9c9b9a2704
Autor:
Annkristin Heine, Stefanie Andrea Erika Held, Solveig Nora Daecke, Chrystel Flores, Peter Brossart
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionSeveral anaplastic lymphoma kinase (ALK)-inhibitors (ALKi) have been approved for the treatment of ALK-translocated advanced or metastatic Non Small Cell Lung Cancer (NSCLC), amongst crizotinib and alectinib. This forces physicians to cho
Externí odkaz:
https://doaj.org/article/af57a727ecae4f81a24f43ecce0cfebe
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.